Korean biotech and pharma · broker research in English

Korean biotech and pharma stocks: analyst target prices and ratings

36 companies with research · 97 reports · 2026-06-29 to 2026-10-26 · close prices of 2026-10-23

Research on Korean drug makers and biotech companies is mostly published in Korean. We collect it and summarise it here in English: each firm's latest target price, the range and median across firms, and the gap to the latest close. Each name links to its own page with the report-by-report list. A sample of broker research, not advice.

Target prices, company by company

Ordered by how many firms stated a target, then by reports — depth of coverage, not a ranking. Swipe the table sideways for dates, close and gap.

CompanyTickerMedian targetLatest targets (range)Firms with a targetReportsFirmsTargets datedLatest reportCloseMedian target vs close
Hanmi Pharmaceutical128940KRW 680,000KRW 530,000 – KRW 730,0001014102026-08-25 to 2026-10-21KRW 361,500 (2026-10-23)+88.1%
Samsung Biologics207940KRW 2,000,000KRW 1,850,000 – KRW 2,000,00091692026-08-31 to 2026-10-22KRW 1,466,000 (2026-10-23)+36.4%
Hugel145020KRW 300,000KRW 250,000 – KRW 340,0005552026-09-23 to 2026-10-21KRW 180,100 (2026-10-23)+66.6%
SK Biopharmaceuticals*326030KRW 160,000KRW 155,000 – KRW 160,0004752026-08-27 to 2026-10-21KRW 76,900 (2026-10-23)+108.1%
GC Biopharma006280KRW 182,500KRW 180,000 – KRW 190,0004442026-10-20 to 2026-10-22KRW 132,200 (2026-10-23)+38.0%
Alteogen196170KRW 450,000KRW 450,000 – KRW 540,0003642026-09-03 to 2026-10-12KRW 224,500 (2026-10-23)+100.4%
Celltrion068270KRW 280,000KRW 260,000 – KRW 300,0003332026-09-28 to 2026-10-23KRW 194,400 (2026-10-23)+44.0%
HK inno.N195940KRW 66,000KRW 56,000 – KRW 68,0003332026-09-10 to 2026-10-13KRW 34,100 (2026-10-23)+93.5%
Dongkook Pharmaceutical086450KRW 31,000KRW 30,000 – KRW 32,0002332026-10-02 to 2026-10-26KRW 24,450 (2026-10-23)+26.8%
Yuhan000100KRW 125,000KRW 110,000 – KRW 140,0002222026-08-19 to 2026-10-16KRW 84,700 (2026-10-23)+47.6%
Dong-A ST170900KRW 50,000KRW 50,000 – KRW 50,0002222026-08-28 to 2026-10-19KRW 34,600 (2026-10-23)+44.5%
HanAll Biopharma009420KRW 70,000One firm1222026-09-28KRW 40,200 (2026-10-23)+74.1%
ST Pharm237690KRW 170,000One firm1212026-09-28KRW 89,900 (2026-10-23)+89.1%
T&L340570KRW 48,000One firm1222026-08-19KRW 24,400 (2026-10-23)+96.7%
Celltrion Pharm Inc.068760KRW 61,000One firm1112026-09-02KRW 37,600 (2026-10-23)+62.2%
Medytox086900KRW 70,000One firm1112026-08-20KRW 67,400 (2026-10-23)+3.9%
Chong Kun Dang Pharmaceutical185750KRW 110,000One firm1112026-08-24KRW 64,700 (2026-10-23)+70.0%
Daebonglsco.,Ltd078140No target stated—022—KRW 6,800 (2026-10-23)Not measured
Qurient Co., Ltd.115180No target stated—022—KRW 19,470 (2026-10-23)Not measured
FutureChem220100No target stated—022—KRW 8,990 (2026-10-23)Not measured
SCL Science Inc.246960No target stated—022—KRW 2,300 (2026-10-23)Not measured
SINSIN PHARMACEUTICAL Co., LTD.002800No target stated—011—KRW 4,080 (2026-10-23)Not measured
Daehan New Pharm023910No target stated—011—KRW 25,300 (2026-10-23)Not measured
HANS BIOMED CORPORATION042520No target stated—011—KRW 17,960 (2026-10-23)Not measured
Bio Solution Co.,Ltd.086820No target stated—011—KRW 5,720 (2026-10-23)Not measured
Kolmar BNH200130No target stated—011—KRW 7,560 (2026-10-23)Not measured
Humedix200670No target stated—011—KRW 23,700 (2026-10-23)Not measured
KANGSTEM BIOTECH CO., LTD.217730No target stated—011—KRW 1,834 (2026-10-23)Not measured
OliX Pharmaceuticals226950No target stated—011—KRW 103,300 (2026-10-23)Not measured
L&C Bio290650No target stated—011—KRW 60,000 (2026-10-23)Not measured
Aptabio Therapeutics Inc.293780No target stated—011—KRW 6,240 (2026-10-23)Not measured
ABL Bio298380No target stated—011—KRW 44,250 (2026-10-23)Not measured
RPbio Inc.314140No target stated—011—KRW 5,430 (2026-10-23)Not measured
ImmuneOncia Therapeutics, Inc.424870No target stated—011—KRW 2,925 (2026-10-23)Not measured
G2GBIO, Inc.456160No target stated—011—KRW 49,700 (2026-10-23)Not measured
Orum Therapeutics, Inc.475830No target stated—011—KRW 16,260 (2026-10-23)Not measured

For each firm we take only its most recent stated target, so a firm that wrote five times counts once. "Targets dated" gives the oldest and newest of those latest targets — a target written weeks ago can sit next to a recent close, and the gap below mixes both dates.

"Median target vs close" is the median of the firms' latest targets divided by the close on 2026-10-23, minus one. It is shown only when both numbers exist. It is a gap between what brokers wrote and what the market paid on one day — not an expected return. When only one firm stated a target, the "median" is that single firm's figure. "No target stated" means none of the reports in our sample carried a target price; it is not a zero. 17 of 36 companies have at least one stated target.

This is a record of what brokers published, not investment advice. It is a sample — the reports our collection picked up between 2026-06-29 and 2026-10-26, not every report written — and the range and median describe that sample, not a market consensus. These are statistics, not a verdict on any stock.

What counts as "biotech and pharma" here

A company is included when the industry code on its record in the Korean regulator's company register (DART) starts with 21 — the whole KSIC division for basic medicinal substances, biological products, medicines and medical supplies — or is 70113, medical and pharmaceutical research and development. Division 21 also holds makers of botulinum toxin, health supplements and medical supplies, and they appear here because that is what they filed. The codes are the Korean Standard Industrial Classification (KSIC); the English names are our rendering of them.

One company is added by name: SK Biopharmaceuticals (326030, marked *). Filed under KSIC 7011 (natural-science research) rather than the narrower 70113, but its business report filed with DART in March 2025 describes a single operating segment, new drugs.

By this rule plus that one addition, 265 listed companies qualify. 36 of them have at least one report in our sample and are in the table above; the other 229 are listed below.

The rule leaves out companies filed under the broader research code 701 (natural sciences and engineering), which does not say whether the research is into medicines. We did not check each one by hand. Examples with research in our sample, left out of the table: Voronoi, Inc. (natural-science and engineering research, KSIC 701), Onconic Therapeutics Inc. (natural-science and engineering research, KSIC 701), PROTEINA CO.,LTD. (natural-science and engineering research, KSIC 701), 3billion Inc. (natural-science and engineering research, KSIC 701). We keep to the filed code rather than choosing companies by hand, so the list can be checked.

Matched the rule, no broker report in our sample

229 companies. No report in our sample is not the same as no research being written — it means our collection did not pick one up between 2026-06-29 and 2026-10-26.

Target prices in other Korean sectors

Same method on every page: a filed industry code, named exceptions with reasons, and what the rule misses.

SMarkets · KLifeDesign InC. · https://seoulmarkets.com/data/korea-biotech-target-prices